Communities, Governments Must Work To Improve Access To Hepatitis C Treatments

HuffPost: Time to Galvanize Efforts to Combat Hepatitis C
Marie-Paule Kieny, chair of the Medicines Patent Pool Governance Board

“…Although we have new hepatitis C treatments that can be up to 100 percent effective for a 12-week course, they simply are not getting to those who need them. Why? Well for starters, more than 70 percent of the estimated 71 million suffering with hepatitis C live in low- and middle-income countries where access to testing, let alone treatment, is limited. … The initial, extremely high price of new drugs has been a major barrier to access, but there are some bright spots on the horizon. … Gilead Sciences signed licensing agreements with 11 Indian manufacturers to locally produce sofosbuvir for developing countries, and 10 generic companies are working through the Medicines Patent Pool to develop low-cost versions of Bristol-Myers Squibb’s daclatasvir, which works best when paired with sofosbuvir. … [W]e have at our disposal effective remedies for hepatitis C if we can deliver them to all patients in need. Unlike HIV treatment which requires a life-time commitment, the battle against hepatitis C can be won over the course of a season. Community involvement and commitments from national governments to eliminate the disease through coordinated prevent, screen, treat, and monitor programs are the way forward…” (12/4).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.